Mengyuan Yang

Dr. Mengyuan Yang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2024 in Biology of Sex Differences
Verified
Journal Article
Open access
PDF file
MYMengyuan Yang
Mengyuan Yang
YFYuzhou Feng
Yuzhou Feng
JLJiajia Liu
Jiajia Liu
HWHong Wang
Hong Wang
SWSijia Wu
Sijia Wu
XZXiaobo Zhou
Xiaobo Zhou
Background: Sexual differences across molecular levels profoundly impact cancer biology and outcomes. Patient gender significantly influences drug responses, with divergent reactions between men and women to the same drugs. Despite databases on sex differences in human tissues, understanding regulations of sex disparities in cancer is limited. These resources lack detailed mechanistic studies on sex-biased molecules. Methods: In this study, we conducted a comprehensive examination of molecular distinctions and regulatory networks across 27 cancer types, delving into sex-biased effects. Our analyses encompassed sex-biased competitive endogenous RNA networks, regulatory networks involving sex-biased RNA binding protein-exon skipping events, sex-biased transcription factor-gene regulatory networks, as well as sex-biased expression quantitative trait loci, sex-biased expression quantitative trait methylation, sex-biased splicing quantitative trait loci, and the identification of sex-biased cancer therapeutic drug target genes. All findings from these analyses are accessible on SexAnnoDB (https://ccsm.uth.edu/SexAnnoDB/). Results: From these analyses, we defined 126 cancer therapeutic target sex-associated genes. Among them, 9 genes showed sex-biased at both the mRNA and protein levels. Specifically, S100A9 was the target of five drugs, of which calcium has been approved by the FDA for the treatment of colon and rectal cancers. Transcription factor (TF)-gene regulatory network analysis suggested that four TFs in the SARC male group targeted S100A9 and upregulated the expression of S100A9 in these patients. Promoter region methylation status was only associated with S100A9 expression in KIRP female patients. Hypermethylation inhibited S100A9 expression and was responsible for the downregulation of S100A9 in these female patients. Conclusions: Comprehensive network and association analyses indicated that the sex differences at the transcriptome level were partially the result of corresponding sex-biased epigenetic and genetic molecules. Overall, SexAnnoDB offers a discipline-specific search platform that could potentially assist basic experimental researchers or physicians in developing personalized treatment plans.

21 January 2023 in Briefings in Bioinformatics
Verified
Journal Article
Closed access
PDF file
SWSijia Wu
Sijia Wu
QXQiuping Xue
Qiuping Xue
MYMengyuan Yang
Mengyuan Yang
YWYanfei Wang
Yanfei Wang
PKPora Kim
Pora Kim
LHLiyu Huang
Liyu Huang
A-to-I RNA editing diversifies human transcriptome to confer its functional effects on the downstream genes or regulations, potentially involving in neurodegenerative pathogenesis. Its variabilities are attributed to multiple regulators, including the key factor of genetic variants. To comprehensively investigate the potentials of neurodegenerative disease-susceptibility variants from the view of A-to-I RNA editing, we analyzed matched genetic and transcriptomic data of 1596 samples across nine brain tissues and whole blood from two large consortiums, Accelerating Medicines Partnership-Alzheimer’s Disease and Parkinson’s Progression Markers Initiative. The large-scale and genome-wide identification of 95 198 RNA editing quantitative trait loci revealed the preferred genetic effects on adjacent editing events. Furthermore, to explore the underlying mechanisms of the genetic controls of A-to-I RNA editing, several top RNA-binding proteins were pointed out, such as EIF4A3, U2AF2, NOP58, FBL, NOP56 and DHX9, since their regulations on multiple RNA-editing events were probably interfered by these genetic variants. Moreover, these variants may also contribute to the variability of other molecular phenotypes associated with RNA editing, including the functions of 3 proteins, expressions of 277 genes and splicing of 449 events. All the analyses results shown in NeuroEdQTL (https://relab.xidian.edu.cn/NeuroEdQTL/) constituted a unique resource for the understanding of neurodegenerative pathogenesis from genotypes to phenotypes related to A-to-I RNA editing.

2 April 2025 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
HWHong Wang
Hong Wang
YZYi Zhang
Yi Zhang
WLWen Li
Wen Li
ZWZhen Wei
Zhen Wei
ZWZhenlong Wang
Zhenlong Wang
MYMengyuan Yang
Mengyuan Yang
Alternative splicing (AS) allows one gene to produce several protein variants, offering valuable predictive insights into cancer and facilitating targeted therapies. Although multi-omics data are used to identify cancer subtypes, AS is rarely utilized for this purpose. Here, we propose a redundancy-reduction contrastive learning-based method (CLCluster) based on copy number variation, methylation, gene expression, miRNA expression, and AS for cancer subtype clustering of 33 cancer types. Ablation experiments emphasize the benefits of using AS data to subtype cancer. We identified 2,921 cancer subtype-related AS events associated with patient survival and conducted multiple analyses including open reading frame annotation, RNA binding protein (RBP)-associated AS regulation, and splicing-related anticancer peptides (ACPs) prediction for therapeutic biomarkers. The CLCluster model is more effective in identifying prognostic-relevant cancer subtypes than other models. The effective annotation of cancer subtype related AS events facilitates the identification of therapeutically targetable biomarkers in patients.

29 October 2025 in Nucleic Acids Research
Verified
Journal Article
Open access
MYMengyuan Yang
Mengyuan Yang
JLJiawei Li
Jiawei Li
JLJiajia Liu
Jiajia Liu
XLXingzheng Lu
Xingzheng Lu
XZXiaobo Zhou
Xiaobo Zhou
YXYungang Xu
Yungang Xu
RNA-binding proteins (RBPs) regulate diverse post-transcriptional processes, yet their functional impacts across multiple molecular layers remain incompletely characterized. KnockRBP (https://knockrbp.xu-bioinfo.com) is presented as a comprehensive, multi-omics database systematically cataloging regulatory changes resulting from genetic perturbation of RBPs. The resource integrates 1453 datasets from GEO, ENA, and ENCORE, encompassing RNA-seq, Ribo-seq, microRNA (miRNA)-seq, and 3′RACE-seq across 639 RBPs, 182 cell lines, and 61 diseases. Regulatory outcomes covered include alternative splicing, alternative polyadenylation, RNA editing, transcript abundance, translation efficiency, and miRNA expression, with all events processed through standardized analytical pipelines and annotated with open reading frame consequences, predicted loss-of-function impacts, and established disease or drug associations. The web interface supports dataset browsing, RBP- and gene-centric multi-omics exploration, transcript structure visualization, and interactive regulatory network navigation, while integrated analytical modules enable prioritization of perturbation-responsive events, cross-layer regulatory inference, and evaluation of clinical relevance. In contrast to existing RBP resources, KnockRBP integrates multi-omics data with perturbation-aware functional annotation, enabling mechanistic investigation and identification of RBP-affected genes and events in post-transcriptional regulation. The database is freely accessible and intended for long-term maintenance, serving as a community resource to advance functional genomics research on RBPs and their roles in human disease.

27 March 2024 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
MYMengyuan Yang
Mengyuan Yang
JLJiajia Liu
Jiajia Liu
PKPora Kim
Pora Kim
XZXiaobo Zhou
Xiaobo Zhou
Splicing factors (SFs) are the major RNA-binding proteins (RBPs) and key molecules that regulate the splicing of mRNA molecules through binding to mRNAs. The expression of splicing factors is frequently deregulated in different cancer types, causing the generation of oncogenic proteins involved in cancer hallmarks. In this study, we investigated the genes that encode RNA-binding proteins and identified potential splicing factors that contribute to the aberrant splicing applying a random forest classification model. The result suggested 56 splicing factors were related to the prognosis of 13 cancers, two SF complexes in liver hepatocellular carcinoma, and one SF complex in esophageal carcinoma. Further systematic bioinformatics studies on these cancer prognostic splicing factors and their related alternative splicing events revealed the potential regulations in a cancer-specific manner. Our analysis found high ILF2-ILF3 expression correlates with poor prognosis in LIHC through alternative splicing. These findings emphasize the importance of SFs as potential indicators for prognosis or targets for therapeutic interventions. Their roles in cancer exhibit complexity and are contingent upon the specific context in which they operate. This recognition further underscores the need for a comprehensive understanding and exploration of the role of SFs in different types of cancer, paving the way for their potential utilization in prognostic assessments and the development of targeted therapies.

12 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
HWHong Wang
Hong Wang
YZYi Zhang
Yi Zhang
WLWen Li
Wen Li
ZWZhenlong Wang
Zhenlong Wang
ZWZhen Wei
Zhen Wei
ZLZhen Li
Zhen Li
Alternative splicing (AS) enables the regulated generation of multiple mRNA and protein products from a single gene. Cancer cells have general, cancer type-specific, and subtype-specific alterations in the splicing process that can have predictive value and contribute to cancer diagnosis, prognosis, and treatment. Currently, multi-omics data have been used to identify the molecular subtype of cancer. However, alternative splicing is rarely used to identify the cancer subtypes. Here, we propose a redundancy-reduction contrastive learning-based method (CLCluster) based on copy number variation, DNA methylation, gene expression, miRNA expression, and alternative splicing for cancer subtype clustering of 33 cancer types. Experimental results demonstrate the superior performance of the proposed CLCluster model in identifying cancer subtypes over the currently available state-of-the-art clustering methods. Moreover, ablation experiments demonstrate the advantages of alternative splicing data for cancer subtyping tasks. We performed multiple analyses for cancer subtype-related AS events, including open reading frame annotation, and RNA binding protein-associated alternative splicing regulation. From our analysis, we identified 2,930 AS events that were associated with patient survival, and ORF analysis showed that 417 of them could cause in-frame and 420 could cause frameshift. we also identified 1,752 RBP-AS regulatory pairs that could be associated with patient survival. Accurate classification of the cancer type using CLCluster, and effective annotation of cancer subtype related AS events can effectively facilitate the identification of patient’s therapeutically targetable AS events.